nation, he looked distress with hypoxemia. Besides headache, he had no neurological deficit. Chest X-ray showed diffused ground glass opacity in both lungs. CT-brain showed normal findings. Lumbar puncture (LP) revealed high open pressure(36 cmH 2 O) with aseptic meningitis-CSF profile. Additionally, encapsulated yeasts were found in CSF. Anti HIV was positive. Amphotericin-B was administered for treatment of disseminated fungal infection, later confirmed as cryptococcosis. The patient became respiratory failure and was assisted with mechanical ventilation on the second day of admission. Then, he was transferred to ICU. Lung protective strategy with neuromuscular-blockade was provided and daily LP was performed to reduce intracranial pressure. Four days later, despite using high doses of sedatives and cisatracurium, the patient had cyclicgasping ( Figure 1A ). Reverse triggering was considered. The patient's neurological signs showed E 1 M 1 V T and sluggish pupil response, which possibly resulted from medications or brain dysfunction. Because reverse triggering was previously reported in patients with brain-death and our patient had a risk of increased intracranial pressure, emergency CT-brain was requested. The CT-brain showed diffused brain swelling with tonsillar herniation ( Figure 1B ). Subsequently, we withheld sedatives and reevaluated neurological signs. The patient still had spontaneous breaths and intact some brainstem-reflexes. Unfortunately, due to irreversible brain damage, he eventually passed away. Background and Aims: It is well-known that ventilation with high volume or pressure may be harmful, causing damage on previously healthy lungs or worsening it in already injured lungs. Up to now, there has been no pharmacological treatment that could prevent ventilatorinduced lung injury (VILI). Melatonin has proven to be effective in acute lung injury. However, melatonin exerts its beneficial properties not only as a direct antioxidant substance but also via melatonin receptor activation.
Ramelteon, a melatonin receptor agonist with highly selective agonist of the high-affinity MT1 and MT2 receptors, is reported to exert antioxidative and anti-inflammatory effects. Ramelteon attenuate VILI remains unclear. The purpose of this study was to determine the effect and mechanism of ramelteon therapy and the association of melatonin receptor on VILI in a rat model.
Methods:
In this study, using a VILI rat model, the SD rats were randomly and equally allocated into 6 groups: group 1 (the control group); group 2 (the VILI group); group 3 (the VILI + melatonin pretreatment group); group 4 (the VILI + melatonin+ luzindole (melatonin receptorantagonist) pretreatment group); group 5 (the VILI + ramelteon (melatonin receptor-agonist) pretreatment group) ; and Group 6 (the VIL + ramelteon + luzindole pretreatment group). The effects of ramelteon and melatonin receptor on VILI were investigated.
Results: We found the protective effect of melatonin in VILI was associated with melatonin receptor. Ramelteon pretreatment markedly reduced lung edema, malondialdehyde level, iNOS level, protein expressions of inflammatory factors (tumour necrosis factor-α, interleukin-1β, interleukin-6, and NF-κB ) and apoptotic factors (caspase-3 and cleaved poly (ADP-ribose) polymerase). Additionally, ramelteon pretreatment significantly increased Hsp70 and interleukin-10 expression. However, the protective effect of melatonin or ramelteon was reduced by the luzindole treatment.
Conclusion:
Our results suggest that melatonin receptors mediate the effects to attenuate VILI and ramelteon is a potential therapeutic drug for treating VILI. 
